MedTrace Logo

Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products

NCT02650674 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-09-14

No results posted yet for this study

Summary

This study aimed at determining the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products in two different ethnic groups.

Conditions

  • Metabolic Disorder

Interventions

OTHER

Product A: NP-0148

Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

OTHER

Glucose solution

Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times

OTHER

Product B: NP-0149

Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

OTHER

Product C: NP-0150

Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

OTHER

Product D: NP-0151

Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

OTHER

Product E: NP-0152

Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Sponsors & Collaborators

  • University of Sydney

    collaborator OTHER

  • Mondelēz International, Inc.

    lead INDUSTRY

Principal Investigators

  • Jennie Brand Miller · University of Sydney

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02650674 on ClinicalTrials.gov